Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 11c; Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.36 -0.03%
Revenue Growth %: +5.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +5.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $60.76 million versus the consensus estimate of $56.85 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2023 revenue of $375-385 million, versus the consensus of $382.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Limoneira (LMNR) Misses Q2 EPS by 8c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
